NextCell´s CEO invited speaker at National conference on Clinical Studies
NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 2019 National Conference on Clinical Studies.
The conference, which is held in Malmö and arranged by the national initiative Clinical Studies Sweden, a collaboration between Vetenskapsrådet (Swedish Research Council) and Sweden´s six healthcare regions, brings together researchers, politicians, and others who are active in the Life Science area. The scope of the event is knowledge exchange and networking, with the topic for the year being “The Value of Clinical studies”. Examples of issues raised are the value clinical studies create and how Sweden should focus their work within Life Science. Mathias Svahn's presentation will elaborate on the work and progress in the ongoing clinical study with drug candidate ProTrans, which NXTCL is currently conducting and the value that the study is expected to generate.
Stay up to date with the latest development in NextCell Pharma
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.